Evidence map›Paper›PMID 38488308›Full record

Trial reportHIV medicine2024

Early HIV viral suppression associated with subsequent 12-month treatment success among people living with HIV in South Africa.

Lauren R Violette, Katherine K Thomas, Jienchi Dorward, Justice Quame-Amaglo, Nigel Garrett, Paul K Drain

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in HIV medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Lauren R VioletteDepartment of Epidemiology, University of Washington, Seattle, Washington, USA.
Katherine K ThomasDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Jienchi DorwardCentre for the AIDS Program of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
Justice Quame-AmagloDepartment of Psychology, University of Washington, Seattle, Washington, USA.
Nigel GarrettCentre for the AIDS Program of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
Paul K DrainDepartment of Epidemiology, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-9569-4097
University of Washington · USCentre for the AIDS Programme of Research in South Africa · ZA

Funding

Point-of-care viral load testing to enable task shifting for chronic HIV careR21AI124719 · NIAID · UNIVERSITY OF WASHINGTON · PI DRAIN, PAUL K, GARRETT, NIGEL JOEL · 2016 to 2017
$336k
Center for AIDS Research, University of WashingtonNational Institute of Allergy and Infectious DiseasesNIAID NIH HHS R21 AI124719South African National Health Laboratory Service Research Trust
6 · The paper itself

Abstract

backgroundWe analyzed the STREAM (Simplifying HIV TREAtment and Monitoring) study to determine risk factors associated with HIV viraemia and poor retention 18 months after initiation of antiretroviral therapy (ART).

methodsThe STREAM study was an open-label randomized controlled trial in Durban, South Africa, that enrolled 390 people living with HIV presenting for their first HIV viral load measurement ~6 months after ART initiation. We used modified Poisson regression with robust standard errors to describe associations between baseline characteristics and three HIV outcomes 18 months after ART initiation: HIV viraemia (>50 copies/mL), poor retention in HIV care, and a composite outcome of poor retention in care and/or HIV viraemia.

resultsApproximately 18 months after ART initiation, 45 (11.5%) participants were no longer retained in care and 43 (11.8%) had viraemia. People with CD4 counts <200 and those with viraemia 6 months after ART initiation were significantly more likely to have viraemia 18 months after ART initiation (adjusted relative risk [aRR] 4.0; 95% confidence interval [CI] 2.1-7.5 and aRR 5.5; 95% CI 3.3-9.0, respectively). People who did not disclose their HIV status and had viraemia after ART initiation were more likely to not be retained in care 12 months later (aRR 2.6; 95% CI 1.1-6.1 and aRR 2.2; 95% CI 1.0-4.8). People with a CD4 count <200 and those with viraemia were more likely to not achieve the composite outcome 18 months after ART initiation.

conclusionsViraemia after ART initiation was the strongest predictor of subsequent viraemia and poor care retention. Understanding early indicators can help target our interventions to better engage people who may be more likely to experience persistent viraemia or disengage from HIV care.

Indexed as

HIV InfectionsViral LoadAdultAnti-HIV AgentsCD4 Lymphocyte CountFemaleHumansMaleMiddle AgedRetention in CareRisk FactorsSouth AfricaTreatment OutcomeViremiaAnti-HIV AgentsHIVpoint‐of‐careretention in careviral failureviral load monitoring

Identifiers

PMID38488308
PMCPMC11405010
OpenAlexW4392882929

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.